SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus)…

Pharvaris N.V. · PRESS-RELEASE filed Apr 2, 2026 at 06:50 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 2, 2026 at 06:50 ET

Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biotech. The focus remains on upcoming catalysts: NDA submission for deucrictibant IR in 1H2026 and topline data from the CHAPTER-3 pivotal trial in 3Q2026. Cash runway of €292M supports operations through key inflection points.

  • EPS of $-0.60 vs. consensus of $-0.62 (3% beat), revenue $0 in line with expectations
  • Cash and cash equivalents: €292 million as of December 31, 2025
  • NDA submission for deucrictibant IR (on-demand HAE treatment) on track for 1H2026
  • Topline data from CHAPTER-3 trial (prophylactic HAE treatment) expected in 3Q2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access